GOG 261: Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Carcinosarcoma
Carboplatin/Taxol is not inferior to Ifos/Taxol in terms of OS and significantly increases PFS, making it a new standard treatment for carcinosarcoma
Study Summaries
KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
Pembrolizumab combined with chemoradiotherapy and then continued post-chemoradiotherapy demonstrates significant improvements in progression-free survival and OS compared to chemoradiotherapy alone
CALLA: Durvalumab versus placebo with chemoradiotherapy
Durvalumab concurrent with chemoradiotherapy was well tolerated but did not significantly improve progression-free survival compared to placebo in a biomarker-unselected all-comers population for locally advanced cervical cancer
SCORPION: Primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer
Neoadjuvant chemotherapy and primary debulking surgery showed similar efficacy in terms of progression-free and overall survival. However, neoadjuvant chemotherapy resulted in significantly lower rates of post-operative complications, suggesting a different toxicity profile
GOG 249: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer
The study did not demonstrate superiority or equivalence due to similar outcomes in both arms. The higher incidence of pelvic/para-aortic nodal failures in the VCB/C arm suggests the importance of pelvic RT in preventing regional recurrences.
KEYNOTE 775: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Lenvatinib plus pembrolizumab significantly improves progression-free and overall survival compared to chemotherapy among patients with advanced endometrial cancer.
GOG 252: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
The duration of PFS was not significantly increased with either IP regimen when combined with bevacizumab, and was better tolerated than IP cisplatin.
ICON 8: Weekly dose-dense chemotherapy in first-line epithelial ovarian
Weekly dose-dense chemotherapy does not significantly improve progression-free survival compared to standard 3-weekly chemotherapy in a predominantly European population.
PRIMA: Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Niraparib significantly extends progression-free survival among patients with newly diagnosed advanced ovarian cancer post-response to platinum-based chemotherapy, regardless of homologous-recombination deficiency status.
SHAPE Trial: Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer
Simple hysterectomy is not inferior to radical hysterectomy in terms of the 3-year incidence of pelvic recurrence and presents a lower risk of urinary complications.